Investor mix
11 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 45% |
| Private equity | 4 | 36% |
| Other / undisclosed | 2 | 18% |
Italian, clinical stage biopharma developing small molecule and antibody therapeutics for chronic inflammatory and autoimmune diseases
11 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 5 | 45% |
| Private equity | 4 | 36% |
| Other / undisclosed | 2 | 18% |